The apolipoprotein B/A-I ratio (mean 1.31) revealed critically high atherogenic potential in CHD patients compared to borderline risk classification by traditional LDL-C (mean 3.6 mmol/l).
Observational (n=210)
Does the apolipoprotein B/A-I ratio provide superior risk stratification compared to traditional LDL-C in patients with chronic coronary syndromes?
The apo-B/apo-A-I ratio may be a superior tool for identifying high residual cardiovascular risk in CHD patients who appear to be at borderline risk based on traditional LDL-C levels.
Abstract. This research aims to provide a comprehensive evaluation of the diagnostic utility of the apolipoprotein B (apo-B) to apolipoprotein A-I (apo-A-I) ratio as a superior risk stratification tool compared to traditional LDL-C in comorbid patients with coronary heart disease (CHD). 210 patients with functional class II-III exertional angina were examined. Results demonstrated that while standard lipidogram values (LDL-C 3.6 ± 0.1 mmol/l) classified patients as "borderline" risk, the apolipoprotein ratio (1.31 ± 0.01) revealed a critically high atherogenic potential. A significant influence of subclinical hypothyroidism (28.1% in women) and obesity on the formation of pathological apolipoprotein profiles was established. The study concludes that integrating apolipoprotein screening is essential for accurately determining residual cardiovascular risk and optimizing preventive therapy in regional clinical practice.
Virmani et al. (Thu,) conducted a observational in Coronary heart disease (CHD) with functional class II-III exertional angina (n=210). Apolipoprotein B/A-I ratio vs. Traditional LDL-C was evaluated on Atherogenic potential / risk stratification. The apolipoprotein B/A-I ratio (mean 1.31) revealed critically high atherogenic potential in CHD patients compared to borderline risk classification by traditional LDL-C (mean 3.6 mmol/l).